Documented case archive2019—2026

Rosie’s
cancer vaccine.

This archive records how Paul Conyngham, UNSW scientists and University of Queensland researchers moved from Rosie’s mast cell cancer to an experimental personalised mRNA treatment—so others can learn from the decisions, methods, collaboration and limits of the work.

Why document it?

To leave a clear evidence trail for researchers, veterinarians, technologists and dog owners: what was tried, who made it possible, what was observed and what one case still cannot tell us.

Paul Conyngham sitting beside his rescue dog RosieArchive image 01
Together in SydneyPhotograph supplied by Paul Conyngham · 2025

Evidence trail

00

The short answer

What was Rosie’s cancer vaccine?

Rosie’s cancer vaccine was an experimental, personalised mRNA immunotherapy designed from molecular differences between her mast cell tumours and healthy tissue. Paul Conyngham used AI-assisted analysis to identify candidate targets; UNSW researchers reviewed and manufactured the mRNA; and a University of Queensland team administered the treatment under veterinary research oversight.

Several tumours reportedly shrank and Rosie’s quality of life improved, but the vaccine was given with a checkpoint inhibitor. This was one experimental case—not a clinical trial, proof of efficacy or a cure.

Read UNSW’s full account
01

Rosie + Paul

One dog. One person who refused to stop looking.

Paul Conyngham adopted Rosie in 2019. The Staffy–Shar Pei cross had been abandoned before finding her way to a Sydney shelter. She soon became, in Paul’s words, his “best mate.”

In 2024, a biopsy confirmed aggressive mast cell cancer. Rosie had multiple surgeries, chemotherapy and immunotherapy, but the disease continued. UNSW reported that veterinarians estimated she might have only one to six months left.

Paul was a machine-learning entrepreneur, not a biologist. He treated the diagnosis as a problem he could learn: read the research, ask better questions, turn tissue into data, and find people with the expertise to challenge and build what the data suggested.

“She’s my best mate.”

— Paul Conyngham, speaking to UNSW

The human story matters

The headline became “AI makes a cancer vaccine.” The documented reality is more interesting: a determined owner used AI to cross an expertise gap, then relied on genomic facilities, RNA scientists, veterinarians and an ethics framework to act responsibly.

02

Rosie’s cancer vaccine timeline

From a Sydney shelter to a first-of-its-kind experiment.

The journey was not a single prompt or sudden breakthrough. It was years of care, months of research, failed routes, expert review and one carefully governed attempt to buy Rosie more good time.

  1. 01

    Paul meets Rosie

    Paul Conyngham adopts a Staffy–Shar Pei rescue who becomes his constant companion.

  2. 02

    Mast cell cancer

    A biopsy confirms advanced mast cell tumours after months of worsening growths on Rosie’s legs.

  3. 03

    Treatment, then data

    After surgery, chemotherapy and immunotherapy fail to control the disease, Paul commissions matched tumour and healthy-tissue sequencing at UNSW.

  4. 04

    Seven candidate targets

    AI-assisted analysis helps Paul compare Rosie’s cancer with her healthy DNA and rank reported tumour-only neoantigen signals.

  5. 05

    The first injections

    UNSW’s RNA Institute turns the reviewed design into mRNA. Rosie receives the experimental vaccine with a checkpoint inhibitor at the University of Queensland.

  6. 06

    A partial response

    Several tumours shrink markedly and Rosie regains mobility and energy. Other tumours do not respond. It is not a cure.

  7. 07

    Rosie’s legacy

    UNSW Science announces that Rosie has died, remembering a dog whose case opened a larger conversation about access to personalised medicine.

See how UNSW documented the early search in 2025
03

How Rosie’s personalised mRNA vaccine was made

Turn the tumour into data. Turn the data into a signal.

A therapeutic cancer vaccine is not designed to prevent cancer. Its aim is to show the immune system molecular flags—called neoantigens—that are present on tumour cells and absent from healthy cells.

  1. 01

    Sequence

    Read DNA from Rosie’s tumour and matched healthy tissue, then check which mutations were active in tumour RNA.

  2. 02

    Compare

    Separate inherited variants from tumour-only changes—the molecular differences that might become immune targets.

  3. 03

    Rank

    Use bioinformatics and AI-assisted tools to investigate altered proteins and prioritise candidate neoantigens.

  4. 04

    Encode

    Translate selected targets into an mRNA sequence, reviewed and produced by trained scientists at UNSW.

  5. 05

    Deliver

    Package the mRNA in lipid nanoparticles and administer it under veterinary research oversight at UQ.

In plain language

mRNA is an instruction, not an edit.

The mRNA gave cells temporary instructions to make selected fragments associated with Rosie’s tumours. The goal was to help immune cells recognise those markers. It did not alter Rosie’s DNA, and it did not contain cancer cells.

What AI helped do

Learn, code, model, rank.

Public accounts describe ChatGPT assisting Paul’s research and code, AlphaFold helping investigate protein structures, and Grok helping produce the final reported construct. These tools accelerated a human-led bioinformatics process.

What AI did not do

Approve, manufacture, inject, prove.

AI did not independently validate the targets, make the physical mRNA, formulate the lipid nanoparticles, grant ethics approval, administer the treatment or establish that it worked.

Read the Ramaciotti Centre’s 2024–25 report
04

The human chain

The vaccine existed because a team formed around Rosie.

Paul led the search and analysis. Specialist teams turned that analysis into something that could be reviewed, manufactured and administered.

01

Paul Conyngham

Rosie’s person · research, bioinformatics, design leadership and coordination

02

Associate Professor Martin Smith

UNSW Ramaciotti Centre for Genomics · matched genomic data and computational expertise

03

Professor Páll Thordarson + team

UNSW RNA Institute · design review, mRNA production and lipid nanoparticle formulation

04

Professor Rachel Allavena + team

University of Queensland · veterinary research oversight and administration

05

Mari Maeda

Canine Cancer Alliance · connected Paul with the UQ research team

Roles above are summarised from UNSW’s public account and independent reporting. Read the technical account in The Scientist

05

Evidence + limits

A meaningful response. Not proof. Not a cure.

Rosie’s case is important because it showed that a highly personalised workflow could reach one real canine patient. It cannot tell us how often the approach will work, for which cancers, or which part of her combination treatment produced the response.

What was observed

  • Several large tumours reportedly shrank markedly.
  • Rosie regained mobility, energy and quality of life.
  • Some tumours did not respond and resistant disease remained.
  • The workflow reached design, manufacture and administration.

What remains unknown

  • The separate effect of the vaccine versus the checkpoint inhibitor.
  • How another dog, tumour type or protocol would respond.
  • The response’s durability without a controlled study.
  • Whether all selected neoantigens generated an immune response.

n = 1

Rosie’s treatment was a single experimental case.

It was not a randomised clinical trial, and no peer-reviewed case report with complete clinical data has been published. The vaccine and a checkpoint inhibitor were used together, so causation cannot be assigned to either component from Rosie’s response.

Read ABC News’ June 2026 follow-up
06

Rosie’s legacy

For Rosie,
with love.

In July 2026, UNSW Science announced that Rosie had died. No public source cited here states her cause of death, and this archive will not speculate.

Her story is larger than a headline about AI. It is the story of a rescue dog who was deeply loved, the extra time Paul fought to give her, and a collaboration that made an experimental form of personalised medicine tangible for the first time in one dog.

Rest easy, Rosie.

Read UNSW Science’s memorial
Further readingExternal record · Gamgee

What came
after Rosie.

Rosie’s one-off treatment became the starting point for Gamgee, the company Paul Conyngham founded to continue investigating personalised cancer-treatment protocols for dogs.

The official follow-up to Rosie’s treatment continues at gamgee.io. Her story also inspired other projects, including rosievaccine.com, which are not affiliated with Paul Conyngham or the original team treating Rosie.

Questions people ask

Clear answers, without the hype

Rosie vaccine FAQs.

Did Rosie’s cancer vaccine cure her?

No. Several tumours reportedly shrank and Rosie regained mobility and energy, but other tumours did not respond. Paul and the scientists involved consistently described a partial response, not a cure.

Did ChatGPT make Rosie’s mRNA vaccine?

No. ChatGPT assisted Paul’s research and coding. Public accounts also describe AlphaFold and Grok being used during analysis and design. Human experts generated the genomic data, reviewed the design, manufactured and formulated the mRNA, secured oversight and administered the treatment.

Was Rosie the first dog to receive a personalised mRNA cancer vaccine?

UNSW Science described Rosie as the first dog to receive a personalised mRNA cancer vaccine. Because “first” claims can depend on definitions and unpublished work, this archive attributes the claim rather than presenting it as an independently proven absolute.

Can I get the same vaccine for my dog?

Rosie’s treatment was a one-off experimental protocol, not a commercially available product. Dog owners should speak with a veterinarian or veterinary oncologist and should not delay established care. Gamgee publishes current information about its investigational work and eligibility on its own website.

What happened to Rosie?

UNSW Science announced in July 2026 that Rosie had died. The public notice did not state a cause, so this archive does not speculate. Rosie’s case remains an important, carefully qualified chapter in canine precision-oncology research.

Sources + method

Last updated 11 August 2026

Follow the evidence.

This documentary prioritises first-party institutional accounts, then independent science and news reporting. Observations are separated from conclusions; conflicting or unsupported claims are not repeated as fact.

Medical + veterinary disclaimer

This site is an educational documentary, not a veterinary service. Rosie’s treatment was experimental and one case cannot predict outcomes for another dog. Nothing here replaces advice from a veterinarian or veterinary oncologist.

Identity + affiliation

RosiesCancerVaccine.com documents Paul and Rosie’s original case and points to Gamgee as Paul’s continuation of that work.